Recurrence in resected gastroenteropancreatic neuroendocrine tumors

Simron Singh, David L. Chan, Lesley Moody, Ning Liu, Hadas D. Fischer, Peter C. Austin, Eva Segelov

Research output: Contribution to journalLetterOtherpeer-review

5 Citations (Scopus)

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities
Original languageEnglish
Pages (from-to)583-585
Number of pages3
JournalJAMA Oncology
Volume4
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Oncology
  • Pancreatic Cancer
  • Gastrointestinal Cancer
  • Pancreatic disease
  • Gastroenterology
  • Gastroenterology and hepatology

Cite this

Singh, S., Chan, D. L., Moody, L., Liu, N., Fischer, H. D., Austin, P. C., & Segelov, E. (2018). Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncology, 4(4), 583-585. https://doi.org/10.1001/jamaoncol.2018.0024
Singh, Simron ; Chan, David L. ; Moody, Lesley ; Liu, Ning ; Fischer, Hadas D. ; Austin, Peter C. ; Segelov, Eva. / Recurrence in resected gastroenteropancreatic neuroendocrine tumors. In: JAMA Oncology. 2018 ; Vol. 4, No. 4. pp. 583-585.
@article{959811676e8e466bad4d6c5838e1bab5,
title = "Recurrence in resected gastroenteropancreatic neuroendocrine tumors",
abstract = "Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities",
keywords = "Oncology, Pancreatic Cancer, Gastrointestinal Cancer, Pancreatic disease, Gastroenterology, Gastroenterology and hepatology",
author = "Simron Singh and Chan, {David L.} and Lesley Moody and Ning Liu and Fischer, {Hadas D.} and Austin, {Peter C.} and Eva Segelov",
year = "2018",
month = "4",
day = "1",
doi = "10.1001/jamaoncol.2018.0024",
language = "English",
volume = "4",
pages = "583--585",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association (AMA)",
number = "4",

}

Singh, S, Chan, DL, Moody, L, Liu, N, Fischer, HD, Austin, PC & Segelov, E 2018, 'Recurrence in resected gastroenteropancreatic neuroendocrine tumors', JAMA Oncology, vol. 4, no. 4, pp. 583-585. https://doi.org/10.1001/jamaoncol.2018.0024

Recurrence in resected gastroenteropancreatic neuroendocrine tumors. / Singh, Simron; Chan, David L.; Moody, Lesley; Liu, Ning; Fischer, Hadas D.; Austin, Peter C.; Segelov, Eva.

In: JAMA Oncology, Vol. 4, No. 4, 01.04.2018, p. 583-585.

Research output: Contribution to journalLetterOtherpeer-review

TY - JOUR

T1 - Recurrence in resected gastroenteropancreatic neuroendocrine tumors

AU - Singh, Simron

AU - Chan, David L.

AU - Moody, Lesley

AU - Liu, Ning

AU - Fischer, Hadas D.

AU - Austin, Peter C.

AU - Segelov, Eva

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities

AB - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities

KW - Oncology

KW - Pancreatic Cancer

KW - Gastrointestinal Cancer

KW - Pancreatic disease

KW - Gastroenterology

KW - Gastroenterology and hepatology

UR - http://www.scopus.com/inward/record.url?scp=85047470755&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.0024

DO - 10.1001/jamaoncol.2018.0024

M3 - Letter

VL - 4

SP - 583

EP - 585

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 4

ER -

Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC et al. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncology. 2018 Apr 1;4(4):583-585. https://doi.org/10.1001/jamaoncol.2018.0024